Molecule intelOpportunity: StrongEssential

Trastuzumab

18 brands · 10 companies · product forms

ATC: L01XC03

Opportunity snapshot

Launch attractiveness
50
Market saturation
27
Price room
100
Regulatory risk
0
18
brands
10
companies
Rs 118,636.52
median price
21
price points
6.18x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 17%

Price room

Across observed sources and strengths
CheapestRs 42,689.03
MedianRs 118,636.52
Most expensiveRs 263,708.44
Spread6.18×
Sources: DRAP-official

max/min price ratio 6.18x across 21 trusted points (Rs 42689.03-263708.44). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 1 live product for Trastuzumab — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(73) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

10 canonical companies and 18 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 6.18x across 21 trusted points (Rs 42689.03-263708.44). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this strong opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.